Gastrointestinal Cancer News

The HER2-targeting antibody-drug conjugate trastuzumab duocarmazine demonstrated clinical activity and appeared safe among patients with heavily pretreated HER2-expressing metastatic cancer, according to results of a dose-escalation and dose-expansion study published in The Lancet Oncology.

The FDA approved bevacizumab-bvzr for the treatment of metastatic colorectal cancer; unresectable, locally advanced, recurrent or metastatic nonsquamous non-small cell lung cancer; recurrent glioblastoma; metastatic renal cell carcinoma; and persistent, recurrent or metastatic cervical cancer.

Experts at a congressional briefing today addressed the need for the U.S. to actively pursue the goal of eradicating HPV and its associated cancers.

In this Guest Commentary, HemOnc Today Next Gen Innovator Van Morris, MD, medical oncologist in the department of gastrointestinal medical oncology at the University of Texas MD Anderson Cancer Center, discusses the results of three important clinical trials in colorectal cancer that were presented at the 2019 ASCO Annual Meeting. The trials investigated established and investigational regimens, including a FOLFOXIRI-bevacizumab treatment strategy in the front-line setting; a novel combination of an oral, multi-kinase inhibitor plus immunotherapy; and the first KRASG12C inhibitor to reach clinical development.

SAN DIEGO — Male sex and advanced age are both risk factors for the development of early-onset colorectal cancer, according to results of a case-control study presented at Digestive Disease Week.

Here we are, back from another bigger, better, more extreme ASCO Annual Meeting.

Certain birth defects appeared significantly associated with increased risk for childhood cancer, according to results of a population-based cohort study of more than 10 million births published in JAMA Oncology.

Race-matched liver transplants significantly improved OS among black patients with early hepatocellular carcinoma, according to study results published in Journal of the American College of Surgeons.

Norman Wolmark, MD, FACS, has been appointed director of NCI cooperative group clinical trials at UPMC Hillman Cancer Center and professor of surgery at University of Pittsburgh School of Medicine.

Cancer Immunotherapy Month is observed every June.